The BRET Office of Career Development is excited to welcome 12 local companies to the 2016 Annual Career Symposium. Meet these employers at both the Networking Huddles and the Networking Reception that day. Learn more about the companies, the employees that work there, and how they contribute to the life science industry.<\/p>\n
The following companies will be in attendance:<\/p>\n
\nAegis Sciences Corporation is a laboratory sciences company providing science-driven testing and consulting services for clients such as healthcare providers, pharmaceutical companies, professional and amateur sports organizations, leading college and university athletic programs, medical examiners, Fortune 500 corporations, and government agencies throughout the United States.<\/p>\n
\naxialHealthcare\u00a0is a cloud-based healthcare solutions company. We have\u00a0pioneered an evidence-driven, predictive pain management solution that\u00a0empowers insurers and equips\u00a0healthcare professionals with the ability to curb the\u00a0overuse of opioids, align\u00a0expenses, ensure safety, and attain optimal pain patient\u00a0outcomes.\u00a0Our mission is to improve the\u00a0well-being of patients in pain\u00a0while\u00a0creating value for our partners.\u00a0We have 25 employees and are located in\u00a0downtown Nashville, Cummins Station.<\/p>\n
\nSince 2009, BenchFly has provided open access and private platforms to labs and\u00a0companies allowing researchers worldwide to communicate via the universallanguage\u2014video.\u00a0Recently, BenchFly launched The ART of Video, an NSF-funded\u00a0project targeting high school students,\u00a0to\u00a0develop the critical thinking and\u00a0communication skills necessary to support the next generation of scientists. BenchFly is located in Nashville and has 10 employees.<\/p>\n
\nBerg is a Boston-based biopharma company focused on taking a bold \u201cback tobiology\u201d approach to therapeutic discovery using its unique AI-based\u00a0Interrogative Biology\u00ae\u00a0platform. \u00a0This platform combines patient biology and\u00a0artificial intelligence-based analytics to engage the differences between healthy\u00a0and disease environments. \u00a0The Nashville-based Berg\u00a0Protein Sciences\u00a0Department supports the research and development efforts of the company.Berg\u2019s mission is to improve the lives of patients. \u00a0We believe that our drug\u00a0candidates and diagnostics will result in faster clinical validation and safer, more\u00a0effective therapies for patients worldwide.<\/p>\n
\nCumberland Emerging Technologies<\/strong><\/em><\/p>\n CET was established in 2000 and is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, Launch Tennessee, and Gloria Pharmaceuticals. CET is a technology development company with dual missions to advance the development of innovative biomedical technologies and stimulate business growth and economic development within Tennessee, locally and regionally. The missions serve a common goal to bring new biomedical products into the commercial marketplace. Technology development is achieved through forming development partnerships, providing a business infrastructure designed for early stage biomedical companies, and harnessing appropriate resources in the corporate, academic, governmental and non-profit sectors.<\/p>\n Cumberland Pharmaceuticals<\/em><\/strong><\/p>\n Cumberland Pharmaceuticals is a specialty pharmaceutical company that\u00a0acquires, develops and commercializes branded\u00a0prescription products designed\u00a0to improve quality of care and address unmet medical needs.With a focus on underserved niche markets, including hospital acute care and\u00a0gastroenterology, we deliver products that serve patients in the U.S. market.Cumberland\u00a0also makes its products available to patients internationally through\u00a0select strategic partnerships.We own the worldwide rights to all our brands. While Cumberland\u2019s commercial\u00a0capabilities are focused on the U.S. market, our business development team is\u00a0actively pursuing opportunities to make our brands available to patients in\u00a0markets around the globe.Our primary mission is to improve upon patient care with products that offer\u00a0clear advantages over existing treatments. We also strive to deliver solutions\u00a0that may help reduce costs for healthcare providers and, ultimately, patients.<\/p>\n \nInsight Genetics is dedicated to improving the lives of cancer patients around\u00a0the world through advanced diagnostics for precision cancer care.<\/p>\n We are a molecular diagnostics company that is working to further precision\u00a0cancer care at times of diagnosis, treatment and therapeutic resistance. We\u00a0specialize in the discovery, development and commercialization of companion\u00a0diagnostics. In addition, Insight Genetics’ CLIA-certified Insight Molecular Labs\u00a0provides unique, high-value cancer testing services to oncologists and\u00a0pharmaceutical companies.<\/p>\n A key priority in cancer care today is increasing the effectiveness of cancer\u00a0treatment through a new generation of therapies that are targeted to specific\u00a0genetic biomarkers. Fast, accurate and comprehensive tests\u00a0\u2013\u00a0called\u00a0companion diagnostics\u00a0\u2013\u00a0are required to make these targeted therapies\u00a0possible. These tests help clinicians pinpoint which targeted therapies may or\u00a0may not work for a particular patient.<\/p>\n We operate at the intersection of drug development and patient care. With a\u00a0high level of scientific expertise and assay development capabilities, as well as\u00a0CLIA and GLP testing services, Insight Genetics spans the spectrum of\u00a0discovery, testing, and commercialization of companion diagnostics. Insight is\u00a0dedicated to developing new technologies and diagnostic tests that will become\u00a0cutting-edge clinical products.Insight Genetics is located in Nashville, TN with over 20 employees.<\/p>\n \nNashBio is a biotech startup that is fundamentally changing drug discovery and\u00a0development processes in biopharma.\u00a0\u00a0Originally spun out of Vanderbilt\u00a0University Medical Center (VUMC), it is the only company of its kind that\u00a0leverages a large databank of rich longitudinal clinical data and genomic\u00a0information collected by VUMC over more than a decade to address pressing\u00a0R&D questions for clients in the biopharmaceutical industry.\u00a0\u00a0The dataset is the\u00a0largest and highest quality of its kind providing an unprecedented opportunity to\u00a0glean useful and valuable information from gene-disease associations.\u00a0\u00a0The\u00a0company leverages this massive databank, along with unique computational\u00a0methods developed at VUMC, to offer a range of precision medicine services to\u00a0biopharma, including accelerated R&D activities and more efficient clinical trial\u00a0design.<\/p>\n \nNextGxDx is a healthcare technology company dedicated to making genetic\u00a0testing more transparent and efficient for stakeholders across the healthcare\u00a0system.<\/p>\n With more than 60,000 genetic tests on the market, the selection, delivery and\u00a0reimbursement of genetic testing is more complicated than ever. With scattered\u00a0information about testing products, inconsistent ordering processes, and inefficient\u00a0coding and billing systems, there is a growing need for tools to navigate this\u00a0explosive field. NextGxDx launched as an IT company dedicated to enhancing the\u00a0transparency of genetic testing data and streamlining processes related to genetic\u00a0test ordering, payment and management for healthcare providers, laboratories and health insurers.<\/p>\n With an outstanding team of physicians, researchers, web developers, data\u00a0scientists and software engineers, NextGxDx launched its proprietary\u00a0GeneSource, GeneConnect and GenePayer solutions to provide data and tools for\u00a0end-to-end genetic testing management, from searching and comparing testing\u00a0products, to tracking orders and results, to payment integrity and forecasting\u00a0trends in pricing and utilization.<\/p>\n As the genetic testing resource, NextGxDx provides comprehensive, intuitive\u00a0solutions that address the specific challenges faced by the medical community.<\/p>\n \nNuSirt BioPharma\u00a0is a privately held biopharmaceutical\u00a0company headquartered in Nashville, TN with research labs in\u00a0Knoxville, TN.<\/p>\n NuSirt is focused on the development of nove\u00a0ldrugs for the treatment\u00a0of\u00a0metabolic\u00a0disorders\u00a0including\u00a0Diabetes,\u00a0Nonalcoholic\u00a0steatohepatitis (NASH), obesity and\u00a0hyperlipidemia.<\/p>\n NuSirt’s platform\u00a0technology\u00a0is based on the\u00a0natural product leucine and uses leucine\u00a0with a very low dose of\u00a0other known therapeutic agents for the treatment of disease.NuSirt has recently completed a\u00a0clinical study\u00a0or the treatment\u00a0of type II diabetes\u00a0and is currently running a clinical study for\u00a0the treatment of NASH.<\/p>\n Clinical results are expected in Q4 2016\u00a0and if successful NuSirt will move this program to a phase 3\u00a0clinical study.<\/p>\n \nSarah Cannon, the global cancer enterprise of Hospital Corporation of America (HCA), offers integrated cancer services with convenient access to cutting-edge\u00a0therapies for those facing cancer in communities across the United States and\u00a0United Kingdom.<\/p>\n By bringing together a network of renowned cancer experts, we are\u00a0collaborating and sharing best practices that address every aspect of the cancer\u00a0journey from screening and diagnosis through treatment and survivorship so\u00a0that patients can receive quality care with improved outcomes.<\/p>\n Our research arm, Sarah Cannon Research Institute (SCRI), formed more than\u00a020 years ago to ensure patients could access cutting-edge therapies closer to\u00a0home. In partnering with leading pharmaceutical\/biotech companies and\u00a0investigators, we offer more than 500 clinical trials annually.<\/p>\n Collectively, our comprehensive patient-centric services ensure that we are\u00a0fulfilling our mission to advance science and transform care.<\/p>\n \nThe Vanderbilt Institute for Clinical and Translational Research (VICTR)\u00a0is Vanderbilt’s virtual home for clinical and translational research. Supported by the\u00a0Vanderbilt Office of Research and the NIH sponsored Clinical and Translational\u00a0Science Award (CTSA), the mission of the institute is to transform the way ideas\u00a0and research discoveries make their way from origin to patient care.\u00a0This is\u00a0accomplished using a multi-faceted approach: through collaboration with a wide\u00a0variety of research partners; by training, nurturing and rewarding participating\u00a0researchers; by funding research; by developing new and innovative ways to\u00a0involve the community in research; by developing new informatics and\u00a0biostatistical systems; and by making available the latest technologies and\u00a0sound research results affecting patient care.<\/p>\n The BRET Office of Career Development is excited to welcome 12 local companies to the 2016 Annual Career Symposium. Meet these employers at both the Networking Huddles and the Networking Reception that day. Learn more about the companies, the employees that work there, and how they contribute to the life science industry. The following companies…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"tags":[],"class_list":["post-181","page","type-page","status-publish","hentry"],"acf":[],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/medschool.vanderbilt.edu\/career-development\/wp-json\/wp\/v2\/pages\/181","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medschool.vanderbilt.edu\/career-development\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/medschool.vanderbilt.edu\/career-development\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/medschool.vanderbilt.edu\/career-development\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medschool.vanderbilt.edu\/career-development\/wp-json\/wp\/v2\/comments?post=181"}],"version-history":[{"count":11,"href":"https:\/\/medschool.vanderbilt.edu\/career-development\/wp-json\/wp\/v2\/pages\/181\/revisions"}],"predecessor-version":[{"id":3000,"href":"https:\/\/medschool.vanderbilt.edu\/career-development\/wp-json\/wp\/v2\/pages\/181\/revisions\/3000"}],"wp:attachment":[{"href":"https:\/\/medschool.vanderbilt.edu\/career-development\/wp-json\/wp\/v2\/media?parent=181"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medschool.vanderbilt.edu\/career-development\/wp-json\/wp\/v2\/tags?post=181"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}http:\/\/www.cet-fund.com\/<\/h4>\n
http:\/\/www.cumberlandpharma.com\/\u00a0<\/a><\/h4>\n<\/div>\n<\/div>\n<\/div>\n
<\/i>Insight Genetics<\/a><\/h4>\n<\/div>\n
www.insightgenetics.com<\/a><\/h4>\n<\/div>\n<\/div>\n<\/div>\n
<\/i>Nashville Biosciences<\/a><\/h4>\n<\/div>\n
www.nashvillebiosciences.com<\/a><\/h4>\n<\/div>\n<\/div>\n<\/div>\n
<\/i>Next GxDx<\/a><\/h4>\n<\/div>\n
www.nextgxdx.com<\/a><\/h4>\n<\/div>\n<\/div>\n<\/div>\n
<\/i>NuSirt BioPharma<\/a><\/h4>\n<\/div>\n
http:\/\/nusirt.com<\/a><\/h4>\n<\/div>\n<\/div>\n<\/div>\n
<\/i>Sarah Cannon Research Institute<\/a><\/h4>\n<\/div>\n
Sarahcannon.com<\/a><\/h4>\n<\/div>\n<\/div>\n<\/div>\n
<\/i>Vanderbilt Institute for Clinical and Translational Research (VICTR)<\/a><\/h4>\n<\/div>\n
Starbrite.vanderbilt.edu<\/a><\/h4>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"